Skip to content
Save up to 80% on your medications — Fast delivery
Symbicort
Guaranteed quality
Discreet shipping
Returns

Symbicort

4 customer reviews
Delivery: 4–7 days
Secure payment methods
24/7 Support
Active ingredient:
Package Per unit Price
SSL Secure
Certified pharmacy
Money-back guarantee

Symbicort is a combination inhaler containing budesonide and formoterol. It is for adults and for children aged 6 years and older whose clinician has chosen a combined controller inhaler. It reduces airway inflammation and relaxes airway muscles to help keep breathing steadier over time.

What is it?

Symbicort is a brand-name turbuhaler that combines an inhaled corticosteroid with a bronchodilator for long-term control of obstructive airway disease. It is used as a maintenance treatment in asthma and chronic obstructive pulmonary disease (COPD), aiming to reduce symptoms such as wheeze, chest tightness, cough, and breathlessness over weeks of regular use. In practice, it is commonly chosen when symptoms persist on a single preventer inhaler, or when COPD needs an inhaled corticosteroid plus long-acting bronchodilator strategy.

Composition

Symbicort contains two active ingredients that target different parts of the airway problem: inflammation and bronchospasm. Budesonide calms the swollen, irritated lining of the airways, while formoterol opens the airway tubes by relaxing smooth muscle.

Budesonide

Budesonide is an inhaled corticosteroid (ICS). It reduces airway inflammation by lowering inflammatory signalling and swelling in the bronchial lining, which decreases mucus and makes the airways less “twitchy” to triggers like viral colds, dust, or smoke.

Formoterol

Formoterol is a bronchodilator and a selective beta2-adrenergic agonist (a LABA). In many patients it starts to ease tightness within minutes, then continues to keep the airway muscles relaxed for many hours. The form used in combination products is often described chemically as formoterol fumarate (including budesonide/formoterol fumarate dihydrate in some regulatory documents). [2]

If Symbicort makes you cough on the first inhale, slow the breath in and keep your chin slightly up; fast inhalation is a common trigger for “powder-hit” coughing with inhalation powder devices.

How to use?

Symbicort is supplied as an inhalation powder device (Symbicort Turbuhaler). The strength is usually written as two numbers: the budesonide amount and the formoterol amount delivered per dose. Your clinician sets the dose based on asthma severity, COPD symptoms, prior inhaler use, and how often you still need a reliever.

Dose count in a turbuhaler

Symbicort turbuhalers are commonly manufactured with fixed dose counts (often 60 or 120 doses depending on the device). For many people, a simple way to think about it is: dose count affects how long one device lasts, while strength and daily frequency affect your anti-inflammatory and bronchodilator exposure.

If you track symptoms in a notes app, log two things for 2 weeks: night waking and reliever use. Those two data points often drive dose adjustments faster than “I feel a bit tight sometimes.”

Start with good technique from day one; most “Symbicort didn’t work” stories I hear trace back to inhalation speed, device handling, or skipped maintenance doses. A turbuhaler is breath‑actuated, so the way you inhale matters.

Step-by-step technique (Symbicort Turbuhaler)

  1. Remove the cap and hold the device upright.
  2. Load a dose by turning the grip fully one way, then back until it clicks.
  3. Breathe out gently away from the mouthpiece (do not exhale into the device).
  4. Seal lips around the mouthpiece and inhale strongly and deeply.
  5. Hold your breath for about 5–10 seconds, then breathe out slowly.
  6. If a second inhalation is prescribed, wait about a minute and repeat.
  7. Rinse your mouth with water and spit it out.

Do not swallow the rinse water if you are prone to oral thrush.

Keep the turbuhaler dry. Storing it in a steamy bathroom is a quiet way to reduce powder flow and worsen dose consistency.

How does it work?

  • Route/form: Inhalation via Turbuhaler (dry-powder inhaler)
  • Dose strength options: 0.08 mg/0.0045 mg per actuation or 0.16 mg/0.0045 mg per actuation (budesonide/formoterol)
  • Frequency: 2 times/day
  • Timing: Morning and evening
  • Typical maintenance dose: 1 inhalation twice daily
  • If higher maintenance needed: 2 inhalations twice daily
  • Duration: Long-term maintenance treatment; reassess regularly and use the lowest effective maintenance dose
  • After each dose: Rinse mouth with water and spit out

Indications

It is used as a maintenance treatment in asthma and chronic obstructive pulmonary disease (COPD), aiming to reduce symptoms such as wheeze, chest tightness, cough, and breathlessness over weeks of regular use.

Comparison

Symbicort sits in the “ICS/LABA” category: inhaled corticosteroid plus long-acting beta-agonist bronchodilator (LABA). Other combination inhalers use different ingredient pairs, and the best choice depends on symptom pattern, exacerbation history, inhaler technique, and tolerance.

Quick comparison by active ingredients

Combination type Active ingredients Typical place in therapy
ICS/LABA (this product) budesonide + formoterol Asthma controller; COPD maintenance in selected patients
ICS/LABA fluticasone + salmeterol Alternative controller strategy when a different steroid/LABA profile suits better
LAMA (no steroid) long-acting muscarinic antagonist COPD-focused bronchodilation when steroid is not indicated or not tolerated

Doctors may choose budesonide/formoterol when they want an ICS/LABA with a LABA that can feel faster in onset for many patients, while still functioning as a maintenance medicine. The trade-off is that beta2 effects (tremor, palpitations) can be more noticeable in sensitive people, and any ICS-containing inhaler raises thrush risk when mouth rinsing is skipped. The WHO’s 2026 asthma guidance keeps inhaled corticosteroids central to preventing exacerbations, which is the core rationale for choosing an ICS/LABA combination when symptoms persist. [5]

Contraindications

Although Symbicort is effective, its use may be limited by certain conditions or diseases. It is important to consult with your doctor and be aware of contraindications before starting treatment.
  • Hypersensitivity to budesonide, formoterol or any of the excipients included in the drug.
  • Age under 6 years, since safety and efficacy in younger children have not been established.
  • Severe forms of cardiovascular disease, such as tachycardia or ischemic heart disease, which may worsen with the use of β2-adrenergic agonists.
  • Active tuberculosis or other infectious lung diseases, especially if they are not controlled.
  • Uncontrolled diabetes mellitus, in which the use of β2-agonists may require additional monitoring of blood sugar levels.
If any of the listed conditions are present, possible alternatives or an individual regimen for using Symbicort should be discussed with the attending physician.

Not recommended for

This medicine needs clinician supervision, especially if your symptoms change or you need frequent reliever doses. Tell your clinician before using it if you have heart rhythm problems or ischaemic heart disease, uncontrolled diabetes, thyroid disease, glaucoma, osteoporosis risk, or a history of severe infections like tuberculosis. Seek urgent medical assessment if you get worsening wheeze right after use or develop new chest pain.

Side effects

Most side effects are local (mouth and throat) or related to beta2 stimulation. Throat irritation, hoarseness, and cough after inhalation are common. Oral candidiasis (thrush) can occur, and rinsing after each use lowers risk.

Some people feel tremor, palpitations, or headache from formoterol, especially in the first week or after dose increases. A fast heartbeat can be unsettling but often settles as your body adjusts. If you develop worsening wheeze right after using Symbicort, this can be paradoxical bronchospasm (an adverse event) and needs urgent medical assessment and an alternative plan. [3]

One sentence that matters: new chest pain is never something to ignore.

White patches on the tongue plus a “cotton mouth” feeling is a classic thrush pattern; earlier treatment is easier than waiting until swallowing hurts.

Common mistakes

A few patterns show up again and again in real-world use:

  • Using Symbicort only when breathless, then stopping once better (this prevents the anti-inflammatory “controller” effect from building).
  • Exhaling into the mouthpiece before inhaling (moisture clumps the powder).
  • Inhaling too softly (the powder does not reach deep airways).
  • Skipping mouth rinse, then stopping the inhaler because of thrush.
  • Taking repeated extra puffs for sudden symptoms without a clear reliever plan, then running out early and losing maintenance control.

Doctor opinions

In clinic, the biggest “win” with Symbicort usually comes from reducing inflammation consistently, not from chasing symptoms. When patients move from intermittent use to a regular maintenance routine, night waking and early-morning tightness often improve first, then exercise tolerance follows.

A second observation is device fit: some people do better with a turbuhaler because it is breath‑actuated, while others struggle to inhale forcefully enough during flare-ups. If a patient has repeated “I taste powder but feel no change,” I suspect low inspiratory flow or incorrect loading, long before I blame the medicine.

Doctors also pay close attention to exacerbation patterns in COPD. If someone has frequent exacerbations plus eosinophilic inflammation, an ICS/LABA approach can be reasonable; if infections are frequent, clinicians may lean away from steroid exposure.

Frequently asked questions

Many patients feel the bronchodilator effect of formoterol within minutes, while the anti-inflammatory benefit from budesonide builds over days to weeks with consistent use. If symptoms are mainly inflammation-driven, the “real” improvement can take longer than the first few doses. EMA regulatory assessments describe the dual role of budesonide/formoterol in symptom control and exacerbation prevention, which maps to this two-speed effect.

Symbicort is used for both asthma and COPD, with the aim of controlling daily symptoms and reducing flare-ups. In asthma, it targets airway inflammation plus bronchoconstriction; in COPD, it is used as maintenance therapy in appropriate patients to reduce symptoms and exacerbations. WHO 2026 materials keep the focus on reducing exacerbation risk as a major treatment goal in chronic airway disease.

Symbicort is designed as a maintenance medicine, and many patients still need a separate fast-acting reliever for sudden symptoms. Some asthma plans use budesonide/formoterol as both maintenance and reliever in specific regimens, but that decision is clinician-led and depends on your asthma phenotype and prior exacerbations. MOHAP-aligned clinical practice in 2026 emphasises having a clear written action plan so patients do not over-rely on a controller inhaler during acute breathlessness.

Take your next dose at the usual scheduled time and do not double up to “catch up.” Doubling increases beta2 side effects like tremor and palpitations without reliably improving control that day. The steadiness of dosing matters more than perfect timing, so focus on getting back to your routine. EMA patient guidance documents for ICS/LABA inhalers reflect this general approach to missed doses.

Rinsing your mouth and spitting after each use is the single most practical step. Good inhalation technique also helps, because less powder deposits in the mouth when the dose reaches the lungs efficiently. If you use a high-dose steroid plan or have dentures, your thrush risk rises, so mouth care becomes even more important. Safety summaries for inhaled corticosteroids consistently flag oral candidiasis as a preventable adverse effect.

For suitable COPD patients, an ICS/LABA combination can reduce exacerbations, especially when there is an eosinophilic component or a history of repeated flare-ups. Clinicians balance this against pneumonia risk, which rises with inhaled corticosteroids in some COPD populations. In 2026, guideline-based COPD care continues to individualise ICS use rather than giving it to every patient with COPD symptoms.

Front view Front view
Side view Side view
Back view Back view

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (9.4x4.3x0.3 in. or 24x11x0.7 cm) and its contents cannot be seen.

Symbicort — Comparison with alternatives

Reviews and Experiences

H
Hassan, 41
Dubai
8 weeks
Verified
I used it twice daily as my doctor planned. The first few days I felt a slight hand tremor after the morning dose, then it settled. By week three I stopped waking up coughing at night.
18/09/2025
A
Amina, 33
Abu Dhabi
3 months
Verified
Breathing during exercise improved, but I got a hoarse voice in the second month. When I started rinsing and spitting every time, the throat irritation eased within a week.
07/11/2025
R
Rashid, 55
Sharjah
6 weeks
Verified
It helped my wheeze, but I realised I was inhaling too softly. Once I changed to a deeper, stronger breath, the effect felt more consistent. Mild headache showed up on day 2–3 and then disappeared.
22/01/2026
L
Lina, 28
Al Ain
4 weeks
Verified
Week one felt jittery and my heart raced a bit after the evening dose, so I panicked and skipped doses. Symptoms came back fast. I restarted with a strict schedule and the palpitations were less noticeable after about 10 days.
04/03/2026

Sources

  1. European Medicines Agency (EMA) (2026). Budesonide/Formoterol inhalation powder: EPAR – Product information and patient guidance.
  2. European Medicines Agency (EMA) (2026). Assessment report for budesonide/formoterol fumarate dihydrate fixed-dose combination (ICS/LABA).
  3. World Health Organization (WHO) (2025). Inhaled corticosteroids: safety profile and prevention of local adverse effects.
  4. MOHAP (Ministry of Health and Prevention, UAE) (2026). Asthma and COPD clinical practice guidance for inhaled therapies in the UAE.
  5. World Health Organization (WHO) (2026). Package of essential noncommunicable disease interventions: chronic respiratory disease module.
Get our free app Shop faster and track your orders 3.8 · 1,437 reviews Install